SCHEMBL6493255

SCHEMBL6493255

COc1cccc(CNc2ccc3oc4ccccc4c3c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.55
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
KDM4E B2RXH2 3/20 0.54
ALDH1A1 P00352 3/20 0.54
GAA P10253 1/20 0.54
HIF1A Q16665 1/20 0.53
EGFR P00533 1/20 0.47
IGF1R P08069 1/20 0.47
HTT P42858 1/20 0.47
APP P05067 1/20 0.47
VKORC1 Q9BQB6 1/20 0.47
ABCB1 P08183 1/20 0.47
ABCG2 Q9UNQ0 1/20 0.47
HPGD P15428 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
CNR2 P34972 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAOA P21397 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495406 0.90 MAPT (0.55) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6490342 0.90 HIF1A (0.51) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6483468 0.88 MAPT (0.58) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6496664 0.88 MAPT (0.61) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6482603 0.88 FFAR1 (0.54) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6483334 0.87 CNR2 (0.56) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6486427 0.85 MEN1 (0.62) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6480515 0.84 MAPK14 (0.45) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6484790 0.84 MAPT (0.57) MAPTMEN1KMT2AKDM4EALDH1A1
SCHEMBL6483310 0.83 MAOB (0.46) MAPTMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US disclosed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 MAPT 2337/4885MEN1 3995/4885KMT2A 412/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 MAPT 3500/4885MEN1 3464/4885KMT2A 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.